Global Biosimilar Monoclonal Antibodies Market

Report ID : 1218 | Published : 2022-03-25 | Pages: | Format:

The Global Biosimilar Monoclonal Antibodies market size was accounted at USD 4.98 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 25% from 2022 to 2030. Biosimilars are biological drugs, and they are large, complex biological molecules produced from living organisms that are often difficult to characterize and therefore difficult to copy. Monoclonal antibody biosimilars play a vital role in treating various chronic and autoimmune diseases. They also represent an opportunity to increase access and reduce costs for patients and healthcare systems.

Global Biosimilar Monoclonal Antibodies market growth is attributed to numerous factors such as biosimilar monoclonal antibodies market include the increasing patent expiries of mAbs, innovation of advanced mAbs, the growing number of biosimilars for oncology treatments, rising demand for lower-priced, cost-efficient biosimilar monoclonal antibodies, growing chronic and autoimmune diseases like cancer, rheumatoid arthritis, diabetes, and the rising older population. Moreover, increasing R&D investments for biological drugs are anticipated to fuel market adoption during the forecast period. Growing R&D activities result in innovative drug products, developmental procedures, and healthcare facilities, thereby boosting market growth.

However, the high cost of development processes, complex mAb manufacturing procedures, region-specific government rules regarding the production and use of biosimilars, lack of scientific standards for biosimilars are expected to hamper the market's growth in the coming years.

The Biosimilar Monoclonal Antibodies Market is segmented based on product, indication, and region. By product, the market comprises the infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products. The infliximab and rituximab segments are projected to hold the highest market share over the forecast period owing to their increasing use in treating various chronic and autoimmune diseases. The market is classified into oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications based on the indication. Among all, The oncology segment is predictable to dominate the market in the coming years due to the surge in biosimilar mAbs approvals for cancer treatments. Regionally, the market is categorized across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. 

North America region dominated this market in 2020 and is expected to continue its trend over the forecast period on account of the favourable reimbursement policies, increasing patent expiration, and the growing rate of biosimilar mAbs approvals. 

Some of the key players operating in the biosimilar monoclonal antibodies market are BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Biosimilar Monoclonal Antibodies Market Snapshot

Chapter 4. Global Biosimilar Monoclonal Antibodies Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Clinical Trial/Pipeline Analysis

4.9. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. Infliximab

5.2.2. Trastuzumab

5.2.3. Rituximab

5.2.4. Adalimumab

5.2.5. Bevacizumab

5.2.6. Cetuximab

5.2.7. Ranibizumab

5.2.8. Denosumab

5.2.9. Eculizumab

5.2.10. Other Pipeline Products

Chapter 6. Market Segmentation 4: By Indications Estimates & Trend Analysis

6.1. By Indications & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indications:

6.2.1. Oncology

6.2.2. Inflammatory & Autoimmune Disorders

6.2.3. Chronic Diseases

6.2.4. Blood Disorders

6.2.5. Other Indication

Chapter 7. Biosimilar Monoclonal Antibodies Market Segmentation 5: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

7.1.2. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Types, 2019-2030

7.1.3. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.1.4. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2019-2030

7.2.2. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2019-2030

7.2.3. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.2.4. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2019-2030

7.3.2. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2019-2030

7.3.3. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.3.4. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2019-2030

7.4.2. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2019-2030

7.4.3. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.4.4. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2019-2030 

7.5. Middle East & Africa

7.5.1. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2019-2030

7.5.2. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2019-2030

7.5.3. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.5.4. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. Pfizer

8.2.2. Novartis

8.2.3. Allergan

8.2.4. Coherus BioSciences

8.2.5. Biocon

8.2.6. Amgen

8.2.7. Boehringer Ingelheim

8.2.8. Celltrion

8.2.9. BioXpress Therapeutics

8.2.10. Intas Pharmaceuticals Limited

8.2.11. Genor BioPharma Co. Ltd

8.2.12. BIOCAD

8.2.13. Dr. Reddys Laboratories Ltd

8.2.14. 3SBio

8.2.15. Reliance Life Sciences

8.2.16. Hisun Pharma

8.2.17. Celgen Biopharma

8.2.18. Torrent Pharmaceuticals

8.2.19. Cadila Healthcare

8.2.20. Mylan Inc.

8.2.21. BioXpress Therapeutics SA

8.2.22. Celltrion

8.2.23. EirGenix, Inc.

8.2.24. Teva Pharmaceutical Industries Ltd.

8.2.25. ALTEOGEN Inc.

8.2.26. Apotex (Apobiologix)

8.2.27. AryoGen Pharmed

8.2.28. Prestige BioPharma (PBP)

8.2.29. PlantForm

8.2.30. Outlook Therapeutics (Oncobiologics)

8.2.31. Shanghai CP Guojian Pharmaceutical

8.2.32. Shanghai Henlius Biotech

8.2.33. Stada Arzneimittel AG

8.2.34. Hetero

8.2.35. mAbxience

Other Prominent Players

Global Biosimilar Monoclonal Antibodies Market, by Product, 2020-2030 (Value US$ Mn)

  • Infliximab
  • Trastuzumab
  • Rituximab
  • Adalimumab
  • Bevacizumab
  • Cetuximab
  • Ranibizumab
  • Denosumab
  • Eculizumab
  • Other Pipeline Products

Global Biosimilar Monoclonal Antibodies Market, by Indication, 2020-2030 (Value US$ Mn)

  • Oncology
  • Inflammatory & Autoimmune Disorders
  • Chronic Diseases
  • Blood Disorders
  • Other Indication

Global Biosimilar Monoclonal Antibodies Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa

Rest of the Middle East & Africa

Competitive Landscape

  • Pfizer
  • Novartis
  • Allergan
  • Coherus BioSciences
  • Biocon
  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • BioXpress Therapeutics
  • Intas Pharmaceuticals Limited
  • Genor BioPharma Co. Ltd
  • BIOCAD
  • Reddys Laboratories Ltd
  • 3SBio
  • Reliance Life Sciences
  • Hisun Pharma
  • Celgen Biopharma
  • Torrent Pharmaceuticals
  • Cadila Healthcare
  • Mylan Inc.
  • BioXpress Therapeutics SA
  • Celltrion
  • EirGenix, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ALTEOGEN Inc.
  • Apotex (Apobiologix)
  • AryoGen Pharmed
  • Prestige BioPharma (PBP)
  • PlantForm
  • Outlook Therapeutics (Oncobiologics)
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Henlius Biotech
  • Stada Arzneimittel AG
  • Other Prominent Players

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Biosimilar Monoclonal Antibodies Market?

Biosimilar Monoclonal Antibodies Market worth $ 36.85 Billion by 2030

CAGR of 25% during the forecast period of 2022-2030.

Our Clients